CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT

ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR BUDESONIDE NASAL SPRAY BY THE NMPA

This announcement is made by CF PharmTech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide shareholders and potential investors with an update on the Group's research and development progress.

INTRODUCTION

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the marketing authorization application (the "**Application**") for the Company's budesonide nasal spray (the "**Product**"), has been accepted by the National Medical Products Administration of the People's Republic of China ("**NMPA**"). The relevant information is hereby announced as follows:

Product name	:	Budesonide nasal spray
Application type	:	Marketing authorization application
Acceptance number	:	CYHS2600272/CYHS2600273
Applicant	:	The Company
Specifications	:	32μg per spray (120 sprays per bottle)/64μg per spray (120 sprays per bottle)
Indications	:	Treatment of (1) seasonal and perennial allergic rhinitis; (2) perennial non-allergic rhinitis; and (3) the prevention of recurrence of nasal polyps after polypectomy and the symptomatic treatment of nasal polyps.

STRATEGIC SIGNIFICANCE

Nasal sprays are complex formulations with high technical barriers. Leveraging its nasal delivery technology platform, the Company has established a comprehensive product matrix covering multiple indications and full-course management for respiratory and rhinitis conditions. The Company's current portfolio in this area includes:

- Azelastine hydrochloride and fluticasone propionate nasal spray (Shufeimin®): The first domestic antihistamine-corticosteroid compound nasal spray, included in the National Reimbursement Drug List (NRDL) in 2023;

- Mometasone furoate nasal spray: A first-line treatment for AR in adults and children aged 3 and above;

- Budesonide nasal spray (The Product): Covering patients aged 6 and above, addressing seasonal acute attacks, perennial maintenance treatment, and nasal polyps; and

- Olopatadine/Mometasone nasal spray: Targeting moderate-to-severe AR symptoms in adults and adolescents aged 12 and above.

The acceptance of the Application for budesonide nasal spray further enriches the Company's product pipeline in the field of allergic rhinitis and reflects the Company's determination and capability to deepen its presence in the respiratory inhalation track and provide high-quality treatment options for patients. The Group will actively communicate with the NMPA and advance subsequent review procedures in accordance with regulatory requirements.

RISK WARNING

The acceptance of the Application represents an administrative step in the review process and does not constitute marketing approval. The Product is subject to further review and assessment by the NMPA, and there is no assurance that the Application will be approved. Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, shareholders and potential investors are advised to make cautious decisions and pay careful attention to investment risks.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, January 30, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.